BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 86.15) Q4 quarterly and 2020 full year forecasted earnings estimates for the periods ending December...
Price: 85.63, Change: -1.96, Percent Change: -2.24 ...
The December 31, 2020 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 87.55) has been raised. This new consensus of...
2020`s forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 88.27) for the year ending December 31, 2020 has been...
| Address | 770 Lindaro Street San Rafael, California 94901 |
| Phone | +1.415.506.6700 |
| Number of Employees | 2,849 |
| Recent SEC Filing | 01/16/2020 4 |
| Chairman & Chief Executive Officer | Jean-Jacques Bienaimé |
| Chief Financial Officer & Executive Vice President | Dan Spiegelman |
| Chief Information Officer | Eduardo E. Von Pervieux |
| Chief Medical Officer & Senior Vice President | Geoffrey M. Nichol |
| Price Open | $84.90 |
| Previous Close | $86.15 |
| 52 Week Range | $62.88 - 100.13 |
| Market Capitalization | $15.2 B |
| Shares Outstanding | 179.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/20/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.17 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.5 B |
| Net Profit Margin | -2.67% |
| Return on Equity | -1.42% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
